108 related articles for article (PubMed ID: 28716987)
1. Control of Pathological Cardiac Hypertrophy by Transcriptional Corepressor IRF2BP2 (Interferon Regulatory Factor-2 Binding Protein 2).
Fang J; Li T; Zhu X; Deng KQ; Ji YX; Fang C; Zhang XJ; Guo JH; Zhang P; Li H; Wei X
Hypertension; 2017 Sep; 70(3):515-523. PubMed ID: 28716987
[TBL] [Abstract][Full Text] [Related]
2. LIM and cysteine-rich domains 1 regulates cardiac hypertrophy by targeting calcineurin/nuclear factor of activated T cells signaling.
Bian ZY; Huang H; Jiang H; Shen DF; Yan L; Zhu LH; Wang L; Cao F; Liu C; Tang QZ; Li H
Hypertension; 2010 Feb; 55(2):257-63. PubMed ID: 20026769
[TBL] [Abstract][Full Text] [Related]
3. NULP1 Alleviates Cardiac Hypertrophy by Suppressing NFAT3 Transcriptional Activity.
Zhang X; Lei F; Wang XM; Deng KQ; Ji YX; Zhang Y; Li H; Zhang XD; Lu Z; Zhang P
J Am Heart Assoc; 2020 Aug; 9(16):e016419. PubMed ID: 32805187
[TBL] [Abstract][Full Text] [Related]
4. Interferon regulatory factor 9 protects against cardiac hypertrophy by targeting myocardin.
Jiang DS; Luo YX; Zhang R; Zhang XD; Chen HZ; Zhang Y; Chen K; Zhang SM; Fan GC; Liu PP; Liu DP; Li H
Hypertension; 2014 Jan; 63(1):119-27. PubMed ID: 24144649
[TBL] [Abstract][Full Text] [Related]
5. GRK5-mediated exacerbation of pathological cardiac hypertrophy involves facilitation of nuclear NFAT activity.
Hullmann JE; Grisanti LA; Makarewich CA; Gao E; Gold JI; Chuprun JK; Tilley DG; Houser SR; Koch WJ
Circ Res; 2014 Dec; 115(12):976-85. PubMed ID: 25332207
[TBL] [Abstract][Full Text] [Related]
6. Hepatic IRF2BP2 Mitigates Nonalcoholic Fatty Liver Disease by Directly Repressing the Transcription of ATF3.
Fang J; Ji YX; Zhang P; Cheng L; Chen Y; Chen J; Su Y; Cheng X; Zhang Y; Li T; Zhu X; Zhang XJ; Wei X
Hepatology; 2020 May; 71(5):1592-1608. PubMed ID: 31529495
[TBL] [Abstract][Full Text] [Related]
7. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.
Wilkins BJ; Dai YS; Bueno OF; Parsons SA; Xu J; Plank DM; Jones F; Kimball TR; Molkentin JD
Circ Res; 2004 Jan; 94(1):110-8. PubMed ID: 14656927
[TBL] [Abstract][Full Text] [Related]
8. Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo.
Grebe C; Klingebiel TM; Grau SP; Toischer K; Didié M; Jacobshagen C; Dullin C; Hasenfuss G; Seidler T
Cardiovasc Res; 2011 Jun; 90(3):521-8. PubMed ID: 21273244
[TBL] [Abstract][Full Text] [Related]
9. Interferon regulatory factor 2 binding protein 2 is a new NFAT1 partner and represses its transcriptional activity.
Carneiro FR; Ramalho-Oliveira R; Mognol GP; Viola JP
Mol Cell Biol; 2011 Jul; 31(14):2889-901. PubMed ID: 21576369
[TBL] [Abstract][Full Text] [Related]
10. Interferon regulatory factor 1 is required for cardiac remodeling in response to pressure overload.
Jiang DS; Li L; Huang L; Gong J; Xia H; Liu X; Wan N; Wei X; Zhu X; Chen Y; Chen X; Zhang XD; Li H
Hypertension; 2014 Jul; 64(1):77-86. PubMed ID: 24732887
[TBL] [Abstract][Full Text] [Related]
11. COX-2 is involved in ET-1-induced hypertrophy of neonatal rat cardiomyocytes: role of NFATc3.
Li H; Gao S; Ye J; Feng X; Cai Y; Liu Z; Lu J; Li Q; Huang X; Chen S; Liu P
Mol Cell Endocrinol; 2014 Feb; 382(2):998-1006. PubMed ID: 24291639
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor receptor-associated factor 3 is a positive regulator of pathological cardiac hypertrophy.
Jiang X; Deng KQ; Luo Y; Jiang DS; Gao L; Zhang XF; Zhang P; Zhao GN; Zhu X; Li H
Hypertension; 2015 Aug; 66(2):356-67. PubMed ID: 26034202
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-328 as a regulator of cardiac hypertrophy.
Li C; Li X; Gao X; Zhang R; Zhang Y; Liang H; Xu C; Du W; Zhang Y; Liu X; Ma N; Xu Z; Wang L; Chen X; Lu Y; Ju J; Yang B; Shan H
Int J Cardiol; 2014 May; 173(2):268-76. PubMed ID: 24631114
[TBL] [Abstract][Full Text] [Related]
14. Caspase recruitment domain 6 protects against cardiac hypertrophy in response to pressure overload.
Li L; Chen W; Zhu Y; Wang X; Jiang DS; Huang F; Wang L; Xiang F; Qin W; Wang Q; Zhang R; Zhu X; Li H; Chen X
Hypertension; 2014 Jul; 64(1):94-102. PubMed ID: 24777975
[TBL] [Abstract][Full Text] [Related]
15. IRF2BP2 is a skeletal and cardiac muscle-enriched ischemia-inducible activator of VEGFA expression.
Teng AC; Kuraitis D; Deeke SA; Ahmadi A; Dugan SG; Cheng BL; Crowson MG; Burgon PG; Suuronen EJ; Chen HH; Stewart AF
FASEB J; 2010 Dec; 24(12):4825-34. PubMed ID: 20702774
[TBL] [Abstract][Full Text] [Related]
16. The transcriptional repressor Nab1 is a specific regulator of pathological cardiac hypertrophy.
Buitrago M; Lorenz K; Maass AH; Oberdorf-Maass S; Keller U; Schmitteckert EM; Ivashchenko Y; Lohse MJ; Engelhardt S
Nat Med; 2005 Aug; 11(8):837-44. PubMed ID: 16025126
[TBL] [Abstract][Full Text] [Related]
17. CIP, a cardiac Isl1-interacting protein, represses cardiomyocyte hypertrophy.
Huang ZP; Young Seok H; Zhou B; Chen J; Chen JF; Tao Y; Pu WT; Wang DZ
Circ Res; 2012 Mar; 110(6):818-30. PubMed ID: 22343712
[TBL] [Abstract][Full Text] [Related]
18. Adiponectin is required for cardiac MEF2 activation during pressure overload induced hypertrophy.
Dadson K; Turdi S; Hashemi S; Zhao J; Polidovitch N; Beca S; Backx PH; McDermott JC; Sweeney G
J Mol Cell Cardiol; 2015 Sep; 86():102-9. PubMed ID: 26196305
[TBL] [Abstract][Full Text] [Related]
19. Critical Role of ADAMTS2 (A Disintegrin and Metalloproteinase With Thrombospondin Motifs 2) in Cardiac Hypertrophy Induced by Pressure Overload.
Wang X; Chen W; Zhang J; Khan A; Li L; Huang F; Qiu Z; Wang L; Chen X
Hypertension; 2017 Jun; 69(6):1060-1069. PubMed ID: 28373586
[TBL] [Abstract][Full Text] [Related]
20. IRF2BP2 Reduces Macrophage Inflammation and Susceptibility to Atherosclerosis.
Chen HH; Keyhanian K; Zhou X; Vilmundarson RO; Almontashiri NA; Cruz SA; Pandey NR; Lerma Yap N; Ho T; Stewart CA; Huang H; Hari A; Geoffrion M; McPherson R; Rayner KJ; Stewart AF
Circ Res; 2015 Sep; 117(8):671-83. PubMed ID: 26195219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
